Azilsartan medoximil

BNF:
2.5.5.2
Status:
Grey
Decision Date:
August 2012
 

Comments

Formulary ARBs are the most cost-effective options.

Grey Drug Classifications

  • 1: Lack of data on effectiveness compared with standard therapy
  • 2: Lack of data on safety compared with standard therapy
  • 5: Less cost-effective than current standard therapy

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app